Items 51 ~ 48 of 2176, Page 6 of 272
Medtronic Supports CMS Ruling on TAVR National Coverage Determination
Medtronic plc (NYSE:MDT) today issued the following statement regarding the final decision memo updating the TAVR National Coverage Determination (NCD...
Medtronic Announces 8 Percent Increase in Cash Dividend
42nd Consecutive Year of Dividend Increases
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
Medtronic Statement Regarding FDA Circulatory System Devices Panel
Medical Devices Advisory Committee on paclitaxel-coated therapies in patients with peripheral artery disease (PAD) in the superficial femoropopliteal ...
AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
LYNPARZA is the Only PARP Inhibitor Approved in Japan
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 201...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
Marks First Approval for KEYTRUDA in SCLC
LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chem...